CANDESARTAN Drug Patent Profile
✉ Email this page to a colleague
When do Candesartan patents expire, and when can generic versions of Candesartan launch?
Candesartan is a drug marketed by Alembic, Apotex, Macleods Pharms Ltd, Mylan, Prinston Inc, Zydus Lifesciences, Apotex Inc, Pharmobedient, and Senores Pharms. and is included in thirteen NDAs.
The generic ingredient in CANDESARTAN is candesartan cilexetil; hydrochlorothiazide. There are twenty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the candesartan cilexetil; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Candesartan
A generic version of CANDESARTAN was approved as candesartan cilexetil; hydrochlorothiazide by PHARMOBEDIENT on December 4th, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for CANDESARTAN?
- What are the global sales for CANDESARTAN?
- What is Average Wholesale Price for CANDESARTAN?
Summary for CANDESARTAN
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 13 |
| Drug Prices: | Drug price information for CANDESARTAN |
| DailyMed Link: | CANDESARTAN at DailyMed |


